[go: up one dir, main page]

WO2003051879A8 - Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors - Google Patents

Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors

Info

Publication number
WO2003051879A8
WO2003051879A8 PCT/EP2002/013973 EP0213973W WO03051879A8 WO 2003051879 A8 WO2003051879 A8 WO 2003051879A8 EP 0213973 W EP0213973 W EP 0213973W WO 03051879 A8 WO03051879 A8 WO 03051879A8
Authority
WO
WIPO (PCT)
Prior art keywords
adp
poly
novel
quinolin
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/013973
Other languages
French (fr)
Other versions
WO2003051879A1 (en
Inventor
Rainer Boer
Steffen Weinbrenner
Frank Dullweber
Thomas Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Priority to AU2002358650A priority Critical patent/AU2002358650A1/en
Publication of WO2003051879A1 publication Critical patent/WO2003051879A1/en
Publication of WO2003051879A8 publication Critical patent/WO2003051879A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds of the formula (1), in which R1 has the meanings indicated in the description, are novel active poly(ADP-ribosyl)transferase (PARP) inhibitors.
PCT/EP2002/013973 2001-12-14 2002-12-10 Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors Ceased WO2003051879A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002358650A AU2002358650A1 (en) 2001-12-14 2002-12-10 Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01000754.0 2001-12-14
EP01000754 2001-12-14
EP02012703.1 2002-06-07
EP02012703 2002-06-07

Publications (2)

Publication Number Publication Date
WO2003051879A1 WO2003051879A1 (en) 2003-06-26
WO2003051879A8 true WO2003051879A8 (en) 2003-11-27

Family

ID=26076431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013973 Ceased WO2003051879A1 (en) 2001-12-14 2002-12-10 Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors

Country Status (2)

Country Link
AU (1) AU2002358650A1 (en)
WO (1) WO2003051879A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407957B2 (en) 2004-08-26 2008-08-05 Maybridge Limited Phthalazinone derivatives

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2547077C (en) 2003-12-01 2015-11-03 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
RU2010108008A (en) 2007-09-14 2011-10-20 Астразенека Аб (Se) Phthalazinone derivatives
AR070221A1 (en) 2008-01-23 2010-03-25 Astrazeneca Ab DERIVATIVES OF FTALAZINONA POLYMERASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME TO PREVENT AND / OR TREAT CANCERIGENE TUMORS, ISCHEMICAL INJURIES AND OTHER ASSOCIATED DISEASES.
DK2346495T4 (en) 2008-10-07 2023-08-28 Kudos Pharm Ltd PHARMACEUTICAL FORMULATION 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
EP3615026B1 (en) 2017-04-28 2021-03-03 Akribes Biomedical GmbH A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
EP3765613A1 (en) 2018-03-13 2021-01-20 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2899757B2 (en) * 1989-06-26 1999-06-02 持田製薬株式会社 Dihydroimidazoquinolinone oxime sulfonic acid derivative
EP0638570A4 (en) * 1992-04-27 1995-04-12 Mochida Pharm Co Ltd Tricyclic compound having antiallergic effect.
JP2002515490A (en) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド Condensed tricyclic compounds that suppress PARP activity
ATE261963T1 (en) * 1999-01-11 2004-04-15 Agouron Pharma TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES
ECSP003637A (en) * 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407957B2 (en) 2004-08-26 2008-08-05 Maybridge Limited Phthalazinone derivatives

Also Published As

Publication number Publication date
AU2002358650A1 (en) 2003-06-30
WO2003051879A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
WO2003051879A8 (en) Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
CA2412560A1 (en) Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
AU2002357773A1 (en) 1,6 naphthyridines useful as inhibitors of syk kinase
WO2001016136A3 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
EP1443925B8 (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
ZA9811178B (en) Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
WO2000076970A3 (en) Serine protease inhibitors
AU3928999A (en) Novel n-oxides
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
AU2002227985A1 (en) Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
AU1626001A (en) 3,4-dihydro-(1h)-quinazolin-2-ones and their use as csbp/p38 kinase inhibitors
WO2004106339A3 (en) 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
ZA200108015B (en) Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases.
WO1999048893A8 (en) Fungicidal 6-(2-halo-4-alkoxyphenyl)-triazolopyrimidines
AU2004200A (en) Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
HK1047276A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
MXPA02009549A (en) Tricyclic imidazopyridines.
AU2003240742A1 (en) 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
AU2002215979A1 (en) Use of pyrazolo(4,3-D)pyrimidines
MXPA03009209A (en) 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds.
AU2002216033A1 (en) Use of pyrazolo(4,3-d)pyrimidines
WO2000064917A3 (en) Synthetic indolocarbazole regioisomers and uses thereof
HK1042090A1 (en) N-substituted imide derivatives with serotonergic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AU BA BR CA CN CO CU DZ EC GE HR HU ID IL IN IS JP KR LT LV MA MK MX NO NZ PH PL RO SG TN UA US VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 26/2003 UNDER (84) EUROPEAN PATENT ADD "SI"

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP